A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results)

被引：0

作者：

Weinblatt, Michael E. ^{[1
]}

Baranauskaite, Asta ^{[2
]}

Niebrzydowski, Jaroslaw ^{[3
]}

Dokoupilova, Eva ^{[4
]}

Zielinska, Agnieszka ^{[5
]}

Sitek-Ziolkowska, Karina ^{[6
]}

Jaworski, Janusz ^{[7
]}

Racewicz, Artur ^{[8
]}

Pileckyte, Margarita ^{[2
]}

Jedrychowicz-Rosiak, Krystyna ^{[9
]}

Zhdan, Vyacheslav ^{[10
]}

Cheong, Soo Yeon ^{[11
]}

Ghil, Jeehoon ^{[11
]}

机构：

[1] Brigham & Womens Hosp, Boston, MA 02115 USA

[2] Lithuanian Univ Hlth Sci, Kaunas, Lithuania

[3] Med Pro Familia, Gdynia, Poland

[4] Med Plus Sro, Uherske Hradiste, Czech Republic

[5] Med Pro Familia, Warsaw, Poland

[6] Med Pro Familia, Katowice, Poland

[7] Reumatika Ctr Reumatol, Warsaw, Poland

[8] Zdrowie Osteomed Sc, Bialystok, Poland

[9] Mazowieckie Ctr Badan Klin, Grodzisk Mazowiecki, Poland

[10] MV Sklifosovskyi Poltava Reg Clin Hosp, Poltava, Ukraine

[11] Samsung Bioepis Co Ltd, Inchon, South Korea

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4